<DOC>
	<DOC>NCT00668525</DOC>
	<brief_summary>This is a short-term study to evaluate the efficacy, safety, and tolerability of escitalopram in adult patients (18 to 65 years of age) with moderate to severe depression. Patients completing the study may be eligible to enter a long-term open-label extension study with escitalopram.</brief_summary>
	<brief_title>Escitalopram in Adult Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Patients must meet Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSMIVTR) diagnostic criteria for Major Depressive Disorder. The patient's current depressive episode must be at least 8 weeks in duration. Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control. Patients with a history of meeting DSMIVTR criteria for: a. any manic or hypomanic episode; b. schizophrenia or any other psychotic disorder; c. obsessivecompulsive disorder. Patients who are considered a suicide risk Patients with a history of seizures (including seizure disorder), stroke, significant head injury, central nervous system tumors, or any other condition that predisposes patients to a risk for seizure.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Escitalopram</keyword>
</DOC>